IONIS PHARMS INC
PharmaIONIS PHARMS INC is a pharmaceutical company with 2 FDA-approved products.
FDA Novel Drug Designations
(2024-2025)See 2 novel approvals →
IONIS PHARMS INC at a Glance
- Fast trial execution (20 months median completion)
Upcoming FDA Decisions
Full Calendar →IONIS PHARMS INC's Key Drugs
IONIS PHARMS INC's core commercial portfolio centers on TRYNGOLZA (AUTOINJECTOR), DAWNZERA (AUTOINJECTOR) — its most strategically important drugs approved in the last 15 years.
IONIS PHARMS INC's Recent FDA Approvals
IONIS PHARMS INC secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
IONIS PHARMS INC's Therapeutic Areas
Disease areas where IONIS PHARMS INC has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
IONIS PHARMS INC Pipeline Snapshot
Active clinical trials for IONIS PHARMS INC across all therapeutic areas, from ClinicalTrials.gov.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • TRYNGOLZA (AUTOINJECTOR) leads revenue
- • 2 key drugs tracked
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 9/20 completed
- • Speed: 20 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (2)
Discontinued (0)
Company Info
- First Approval
- 2024-12-19
- Latest
- 2026-06-24
- Applications
- 2
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges